

Complexion  
Patient

**ZAUXIT**

Fluoxetine HCl 20mg Capsules

*Changes the  
complexion*

Changes the  
of Depressed

Diagnostic Criteria for

## Depression

As proposed by American Psychiatric Association



- ▶ Depressed mood most of the day
- ▶ Markedly diminished interest in all activities most of the day
- ▶ Significantly weight loss or weight gain (at least 5% in one month)
- ▶ Insomnia or Hypersomnia
- ▶ Psychomotor retardation or Agitation
- ▶ Fatigue or loss of energy
- ▶ Feeling or worthlessness or excessive guilt
- ▶ Diminished ability to think or concentrate, or indecisiveness
- ▶ Recurrent thoughts of death or suicide; a suicide attempt or a specific plan for suicide.

At least five of the symptoms listed above, including at least one of the first two, must be present nearly every day over a period of two weeks then your patient will be categorized under depression.

Reference: Davidson's Principles & Practice of Medicine 17th Edition, Page 1001

**"Medicines For All"**



**Zafa Pharmaceutical Laboratories (Private) Limited**  
L-1/B, Block-22, FEDERAL 'B' INDUSTRIAL AREA, KARACHI-75950 (PAKISTAN)  
Email: zafaph@cyber.net.pk Website: www.zafa.com.pk



# ZAUXIT

Fluoxetine HCl 20mg Capsules

**1st** Line Anti-depressant

Highly Recommended

IN

Depression

Obsessive Compulsive Disorders

- Proven efficacy & tolerability
- Safety in overdose
- Preferred choice in elderly patients
- Simplicity of dosage
- Cost effective



# ZAUXIT

Fluoxetine HCl 20mg Capsules

**Dosage:**

Initial Therapy: 20mg once a day

Max. Dose: 80mg/day

\*FDA Approved Raw Material Source

**COST EFFECTIVE:**



## Brief Prescribing Information:

**Description:** ZAuxIT (Fluoxetine HCl) is a selective serotonin re-uptake inhibitor (SSRI) which specifically inhibits the re-uptake mechanism, resulting in increased concentrations of serotonin in the synaptic cleft and hence improves neurotransmission. **Composition:** Each capsule contains Fluoxetine Hydrochloride 20mg. **Indications:** ZAuxIT is indicated for the treatment of depression and its associated anxiety & obsessive-compulsive disorders. **Contraindications:** Known hypersensitivity to the drug. ZAuxIT should not be used in combination with monoamine oxidase inhibitor (MAOI) or within 14 days of discontinuing therapy with MAOI, since Fluoxetine and its major metabolites have very long elimination half lives, at least 5 weeks should be allowed after stopping ZAuxIT & before starting MAOI. **Warnings:** Rash and possibly allergic event may occur so upon the appearance of rash or other possibly allergic phenomena for which an alternative etiology cannot be identified, ZAuxIT should be discontinued. **Precautions:** ZAuxIT (Fluoxetine HCl) should be used with caution in reduced doses in patients with impaired hepatic or renal function. It should be used with caution in patients with epilepsy or history of such disorders. **Use in Pregnancy and Lactation:** There are no adequate or well controlled studies so caution should be exercised when Fluoxetine administered to such patients. **Dosage and Administration:** A dose of 20mg/day administered in the morning, is recommended as the initial dose. A dose increase may be considered after several weeks if no clinical improvement is observed. Doses above 20mg/day should be administered on a b.i.d schedule (i.e. morning & noon) and should not exceed a maximum dose of 80 mg/day. **Adverse Reaction:** The most common adverse reactions are nervous system complaints including anxiety, nervousness and insomnia, drowsiness and fatigue or asthenia, tremor, sweating, gastrointestinal complaints including anorexia, nausea, diarrhoea, and dizziness or lightheadedness. **Presentation:** ZAuxIT is available in blister pack of 20 capsules.